{"name":"Dilafor AB","slug":"dilafor-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DF 01","genericName":"DF 01","slug":"df-01","indication":"Hypertension","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DF01","genericName":"DF01","slug":"df01","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DF 01","genericName":"DF 01","slug":"df-01","phase":"phase_2","mechanism":"DF 01 is a small molecule drug that targets the mechanism of action of a specific enzyme.","indications":["Hypertension"],"catalyst":""},{"name":"DF01","genericName":"DF01","slug":"df01","phase":"phase_2","mechanism":"DF01 is a small molecule that targets the [unknown] mechanism.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPZFBqSGNOR2JBb3RkUmVTdGk3aWhUVjh1ZTh1bXF3cF9ySzhobXMtXzNjaFhQVDNjNmgxVEJ0X0V3cmxzekIxVl9td3k2OWNDVVlnM0FicHhPdXhaczMxZTFlYk56U0JRWWRDRDNXVzdmODdkcmdvdHZab2E1OEhoeGhuN0FMYTdIX0lScFhheEdHejdTUmc?oc=5","date":"2026-01-21","type":"deal","source":"The Pharma Letter","summary":"Dilafor signs deal with Exeltis for tafoxiparin - The Pharma Letter","headline":"Dilafor signs deal with Exeltis for tafoxiparin","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}